Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2020-10-13 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2020年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2020, providing estimated net profit and earnings per share figures for the period January 1 to September 30, 2020. It explicitly states that the forecast is unaudited and preliminary, with final audited financial data to be disclosed in the official third quarter report. The document is relatively short (1909 characters) and serves as an announcement of expected financial results rather than a full financial report containing actual financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. 9M 2020
2020-10-13 Chinese
关于诉讼进展情况公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of ongoing litigation cases. It details the filing of a civil lawsuit, the receipt of court decisions, the appeal process, and the potential impact on the company's profits. The document also states that there are no other significant undisclosed litigation or arbitration matters. The content is focused on legal proceedings and updates rather than financial results, management changes, or other report types. The document length is short (1150 characters), and it is clearly an announcement about legal matters, not a full legal report or audit. Therefore, the most appropriate classification is Legal Proceedings Report (LTR).
2020-09-02 Chinese
关于孙公司注销完成的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of the deregistration (注销) of a subsidiary company. It references a prior announcement about the liquidation and deregistration process and states that the subsidiary will no longer be consolidated in the financial statements. The document is short (700 characters) and serves as an official notice of a corporate event rather than a financial report or detailed management discussion. There is no financial data, no meeting materials, no voting results, no executive changes, no earnings information, or other report content. This fits best with a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2020-08-24 Chinese
独立董事关于公司第八届董事会第二次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent directors' opinion on matters discussed at the company's eighth board of directors' second meeting, including related party transactions, external guarantees, and senior management personnel adjustments. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content focuses on governance and management changes rather than financial results or audit findings. The document length is short (1207 characters) and does not contain financial statements or detailed financial data. It is not a report publication announcement but a governance-related statement. Therefore, the document best fits the category of Board/Management Information (MANG), as it announces changes in senior management and provides independent directors' opinions on board matters.
2020-08-24 Chinese
关于公司及子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase wealth management products. It details the amounts, dates, and types of financial products purchased, risk disclosures, and risk control measures. The document is a specific update on capital usage and investment activities rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly/yearly results. The document length is 4668 characters, which is relatively short and focused on a specific financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-08-24 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '金陵药业股份有限公司 2020 年半年度报告全文' which translates to 'Jinling Pharmaceutical Co., Ltd. 2020 Semi-Annual Report Full Text'. It contains detailed financial data, management discussion and analysis, business overview, financial indicators, and other comprehensive information for the half-year period ending June 30, 2020. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes financial statements, profit and loss analysis, business segments, risk factors, and operational details typical of an Interim / Quarterly Report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.